China SXT Pharmaceuticals (SXTC) Notes Payables (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Notes Payables for 8 consecutive years, with $355175.0 the latest figure, recorded in Q1 2026.

• Quarterly Notes Payables fell 49.42% year-over-year to $355175.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $355175.0 (down 49.42% YoY) and the FY2026 annual result came in at $355175.0, down 49.42% from the prior year.
• Notes Payables slipped to $355175.0 in Q1 2026 per SXTC's latest filing, from $976367.0 in the prior quarter.
• Over the last five years, Notes Payables for SXTC reached as high as $976367.0 in Q3 2025 and fell as low as $5822.0 in Q3 2023.
• A 4-year average of $486034.1 and a median of $493054.0 in 2024 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2024 — Notes Payables soared 11960.87% — and 2026, when it tumbled 49.42%.
• Year by year, Notes Payables stood at $5822.0 in 2023, then surged by 11960.87% to $702184.0 in 2024, then soared by 39.05% to $976367.0 in 2025, then sank by 63.62% to $355175.0 in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $355175.0, $976367.0, and $702184.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.